Single-center, randomized, double-blind, double-dummy, active and placebo-controlled, five-period crossover trial of intranasal morphine [Egalet-001] versus MS Contin for the treatment of pain in non-dependent, recreational opioid users [Category 3 abuse-deterrent intranasal HAL study]

Trial Profile

Single-center, randomized, double-blind, double-dummy, active and placebo-controlled, five-period crossover trial of intranasal morphine [Egalet-001] versus MS Contin for the treatment of pain in non-dependent, recreational opioid users [Category 3 abuse-deterrent intranasal HAL study]

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2017

At a glance

  • Drugs Morphine (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Sponsors Egalet
  • Most Recent Events

    • 20 May 2017 Results of this and another phase I study presented at the 36th Annual Scientific Meeting of the American Pain Society.
    • 22 Sep 2016 Results published in an Egalet media release.
    • 22 Sep 2016 Results from this and intranasal abuse potential trial (see CTP 700252740) published in Pain Medicine, according to an Egalet Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top